!%Carl Zeiss Meditec Inc.%! of Dublin, Calif., has announced that the Mel 80 excimer laser has received premarket approval for the treatment of hyperopia, or farsightedness, from the FDA. This hyperopia indication complements existing FDA-approved applications of the surgical laser for myopia and astigmatism, according to the company. It will allow the company to offer a broader range of treatment options to refractive surgeons and their patients. The device combines high-grade optics and advanced laser technology. Clinical results of the Mel 80 study for hyperopia were presented in March at the American Society of Cataract and Refractive Surgery in San Diego.